Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated? (Q34583277)

3 August 2017

1 reference

title

Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated? (English)

1 reference

3 August 2017

main subject

gram-positive bacteria

0 references

author name string

Johnson AP

series ordinal

1

1 reference

3 August 2017

Livermore DM

series ordinal

2

1 reference

3 August 2017

Tillotson GS

series ordinal

3

1 reference

3 August 2017

publication date

1 December 2001

1 reference

Journal of Hospital Infection

3 August 2017

published in

1 reference

3 August 2017

volume

49 Suppl A

1 reference

3 August 2017

page(s)

S3-11

1 reference

Antibiotic resistance among clinically important gram-positive bacteria in the UK.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Surveillance studies: how can they help the management of infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

The life and times of the Enterococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Current perspectives on glycopeptide resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Antimicrobial resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

The fluoroquinolone antibacterials: past, present and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

Development of daptomycin for gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

https://api.crossref.org/works/10.1016%2FS0195-6701%2801%2990029-5

7 January 2021

10.1016/S0195-6701(01)90029-5

Identifiers

DOI

1 reference

3 August 2017

1 reference